- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00648232
HIV Counseling and Testing and Linkage to Care in Uganda
Přehled studie
Postavení
Podmínky
Detailní popis
HIV is a virus that can lead to acquired immunodeficiency syndrome (AIDS), a disease that breaks down the immune system and allows for entry of life-threatening secondary infections. HIV is a major global health concern, with countries in Africa undergoing a severe HIV/AIDS crisis. The number of new cases of HIV infection in Africa continues to rise, making disease prevention methods imperative. Important to the prevention process are early testing, educational counseling on HIV and how to reduce sexual-risk behavior, and connecting people with HIV infection to services that offer medical treatment and social support. However, the most effective strategy for fully integrating HIV counseling, testing, and medical care access is not known. This study will compare the effectiveness of brief versus detailed HIV counseling sessions, paired with either referrals to HIV-specific medical care or usual care, in reducing HIV risk behavior and in increasing treatment adherence in Uganda.
Participation in this study will last 12 months. All participants will undergo an initial interview to obtain basic information on previous HIV testing and status. Participants will then be assigned randomly to receive a brief or more detailed counseling session given before and after HIV testing. Participants assigned to the brief counseling session will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and available services for people infected with HIV. Participants assigned to the detailed counseling session will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV. After pretest counseling, participants in both groups will undergo a blood draw for HIV testing. All participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
Participants who are found to be infected with HIV will be assigned randomly to receive enhanced referrals to HIV-specific medical care or referrals to usual care. Participants receiving the enhanced referrals will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area. After leaving the hospital, participants will receive reminder telephone calls 1 week before their first scheduled visits at the HIV clinics. Participants receiving referrals to usual care will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services. At Months 3, 6, 9, and 12, participants in both groups will be interviewed about contact information, overall health, current medications, sexual history, health services utilized, and any repeat HIV tests. Participants who are not infected with HIV may be randomly selected to undergo the same follow-up interviews as the HIV infected participants.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
-
Kampala, Uganda, 7072
- Makerere University/Mulago Teaching Hospital, Uganda
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Willing to receive HIV test results
- Willing to provide adequate contact information
- Possesses sufficient cognitive ability to provide informed consent and participate in the interventions, as determined subjectively by the Regulatory Coordinator (patient with altered mental status or who is otherwise too ill to participate in the consent process will be excluded)
- Planned local residence over the next year after study entry (within a reasonable distance; approximate radius of 25 km of Kampala city center)
- Fluent in Luganda or English
Exclusion Criteria:
- Self-reported HIV-infected serostatus (defined as ever receiving an HIV-positive test result)
- Self-reported HIV test within the 12 months before study entry
- Any condition that, in the opinion of the study staff, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: A
Participants will receive voluntary brief HIV counseling and testing plus enhanced linkage to care.
|
Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV.
After pretest counseling, participants will undergo a blood draw for HIV testing.
Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
Participants will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area.
After leaving the hospital, participants will receive reminder telephone calls 1 week before their scheduled visits at the HIV clinics.
|
Experimentální: B
Participants will receive voluntary brief HIV counseling and testing plus routine referral to care.
|
Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV.
After pretest counseling, participants will undergo a blood draw for HIV testing.
Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.
|
Experimentální: C
Participants will receive voluntary longer, more detailed HIV counseling and testing plus enhanced linkage to care.
|
Participants will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area.
After leaving the hospital, participants will receive reminder telephone calls 1 week before their scheduled visits at the HIV clinics.
Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV.
After pretest counseling, participants will undergo a blood draw for HIV testing.
Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
|
Experimentální: D
Participants will receive voluntary longer, more detailed HIV counseling and testing plus routine referral to care.
|
Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.
Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV.
After pretest counseling, participants will undergo a blood draw for HIV testing.
Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
|
Aktivní komparátor: E
Participants who are found to be healthy will receive voluntary brief HIV counseling and testing only.
|
Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV.
After pretest counseling, participants will undergo a blood draw for HIV testing.
Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
|
Aktivní komparátor: F
Participants who are found to be healthy will receive voluntary longer, more detailed HIV counseling and testing only.
|
Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV.
After pretest counseling, participants will undergo a blood draw for HIV testing.
Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Reduction in HIV risk behavior among inpatients after discharge
Časové okno: Measured at Months 3, 6, 9, and 12
|
Measured at Months 3, 6, 9, and 12
|
Receipt of opportunistic infection (OI) prophylaxis, adherence to antiretroviral therapy (ART), and reduction in mortality
Časové okno: Measured at Months 3, 6, 9, and 12
|
Measured at Months 3, 6, 9, and 12
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Number of infections averted per patient randomized to each of the four intervention strategies
Časové okno: Measured at Month 12
|
Measured at Month 12
|
Spolupracovníci a vyšetřovatelé
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Thomas J. Coates, PhD, UCLA David Geffen School of Medicine
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- R01MH077512 (Grant/smlouva NIH USA)
- DABHR 9A-ASGA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na HIV infekce
-
Ottawa Hospital Research InstitutePfizerDokončenoHIV infekce | HIV-1 infekce | Mycobacterium Avium Complex (MAC)Kanada
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...AbbottDokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-IntracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy, Tanzanie
-
AbbottDokončenoHIV infekce | Intracelulární infekce Mycobacterium AviumSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-IntracellulareSpojené státy
-
PfizerDokončenoHIV infekce | Infekce Mycobacterium Avium-IntracellulareSpojené státy